New Zealand markets open in 7 hours 3 minutes

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.7700+0.0148 (+1.96%)
As of 09:56AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.7552
Open0.7480
Bid0.7410 x 4000
Ask0.7757 x 2200
Day's range0.7410 - 0.7800
52-week range0.4900 - 13.4900
Volume83,852
Avg. volume2,517,925
Market cap51.036M
Beta (5Y monthly)0.83
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine

    Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaperBriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines, according to IIBR findings RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, who spoke at the Eli Hurvitz Institute f

  • GlobeNewswire

    NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments

    ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Administration guidelinesNRx is also making ZYESAMI available as an investigational medicine under the Federal Right to Try Act1ZYESAMI is available to patients who have progressed despite treatment with remdesivir and other approved medicines and who are not able

  • GlobeNewswire

    NRx Responds to Relief’s Allegations of January 14, 2022

    Neither NRx nor Jonathan Javitt accused current Relief management or board of a criminal past. The lawsuit identifies FINRA actions against Dr. Sevelraju, prior securities investigation, and civil fines against Dr. John Paul Waymack, and a prior securities fraud conviction, incarceration, and SEC fines against Adam Gottbetter.NRx provided all financial records to Relief on December 6, 2021, yet Relief advised the SEC on December 16, 2021, that it received no records from NRx.NRx looks forward to